Basic Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. May 26, 2022; 14(5): 330-346
Published online May 26, 2022. doi: 10.4252/wjsc.v14.i5.330
Human amniotic fluid stem cell therapy can help regain bladder function in type 2 diabetic rats
Ching-Chung Liang, Steven W Shaw, Yung-Hsin Huang, Tsong-Hai Lee
Ching-Chung Liang, Yung-Hsin Huang, Female Urology Section, Department of Obstetrics and Gynecology, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
Steven W Shaw, Division of Obstetrics, Department of Obstetrics and Gynecology, Taipei Chang Gung Memorial Hospital, Taipei 105, Taiwan
Steven W Shaw, Prenatal Cell and Gene Therapy Group, Institute for Women’s Health, University College London, London WC1E 6BT, United Kingdom
Tsong-Hai Lee, Stroke Center and Department of Neurology, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
Author contributions: Liang CC and Lee TH designed the study and wrote the manuscript; Liang CC and Lee TH were responsible for obtaining funds; Liang CC, Shaw SW, and Huang YH collected the tissue samples; Liang CC, Shaw SW, and Huang YH conducted the experimental analysis; Huang YH performed all laboratory tests; and all authors read and approved the final manuscript.
Supported by the Linkou Chang Gung Memorial Hospital grants, No. CMRPG3J0951 and No. CMRPG3H1041-2; and Ministry of Science and Technology Taiwan grants, No. MOST 107-2314-B-182A-101 and No. MOST 109-2314-B-182A-084.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board at Linkou Chang Gung Memorial Hospital (No. 201701998A3).
Institutional animal care and use committee statement: The present work was approved by the Institutional Ethics Committee for the Care and Use of Experimental Animals (No. 2017121812). It was carried out in accordance with USP guidelines, ARRIVE guidelines, and the EC Directive 2010/63/EU for animal experiments (http://ec.europa.eu/environment/chemicals/Lab_animals/Legislation_en.htm).
Conflict-of-interest statement: The authors have no conflicts of interest to disclose.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tsong-Hai Lee, PhD, Professor, Stroke Center and Department of Neurology, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, No. 5, Fu-Hsing Street, Kweishan, Taoyuan 333, Taiwan. thlee@adm.cgmh.org.tw
Received: October 26, 2021
Peer-review started: October 26, 2021
First decision: December 4, 2021
Revised: January 3, 2022
Accepted: April 25, 2022
Article in press: April 25, 2022
Published online: May 26, 2022
Processing time: 211 Days and 21.6 Hours
Core Tip

Core Tip: Diabetic patients with bladder dysfunction are often resistant to currently available therapies. Stem cells demonstrate the efficacy in preclinical studies of diabetic bladder dysfunction. Human amniotic fluid stem cells (hAFSCs) can be obtained from amniotic fluid, and phenotypically and genetically stable, indicating that hAFSCs can be used as a novel source of cell therapy. Here, we demonstrated that, although it is insulin but not hAFSCs therapy that can help recover the bladder dysfunction caused by diabetes mellitus (DM), both insulin and hAFSCs treatment can help to regain bladder function to near the levels of control. Our study highlights the potential of hAFSCs for cell replacement and regeneration therapy for DM.